Jyri Teras
A5011535785- Global Health and Surgery
- Cardiac, Anesthesia and Surgical Outcomes
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Sarcoma Diagnosis and Treatment
- Surgical site infection prevention
- Abdominal vascular conditions and treatments
- Mast cells and histamine
- Colorectal Cancer Screening and Detection
- IgG4-Related and Inflammatory Diseases
- Reconstructive Surgery and Microvascular Techniques
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Autoimmune and Inflammatory Disorders
- COVID-19 and healthcare impacts
- Eosinophilic Disorders and Syndromes
- Asthma and respiratory diseases
North Estonia Medical Centre
2019-2024
Background80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative breast, colorectal, gastric surgery hospitals worldwide, focusing the effect disease stage complications mortality.MethodsThis was multicentre, international prospective cohort study consecutive adult patients undergoing for primary or requiring skin incision done under general neuraxial...
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial-II, SLN+ no longer undergo CLND prior to therapy. A retrospective analysis clinical outcomes treated therapy after July 2017 was performed 21 international cancer centers. Of 462 who received therapy, 326 anti-PD-1 without immediate (IM) CLND, while...
9572 Background: For pts with resected CM, adjuvant anti-PD1 is approved for AJCC v8 stage IIB–IV and BRAFi/MEKi III–IV disease. Nonetheless, there remains a subgroup of within stages IB/IIA, which at high risk relapse death, accounts considerable share overall CM mortality (1), lacks access to such therapy. Thus, clinical trials in this “early”-stage setting may be merited. However, not detectable via staging alone. A prognostic 7-IHC assay that was developed (2), analytically (3)...
Sarcoma is a heterogeneous group of malignancies comprising almost 80 subtypes bone and soft tissue cancers. Previously, all were managed identically. Advancements in biological genetic studies have revealed that sarcoma display varying characteristics therefore require tailored treatments. Locally advanced both the trunk extremities can present significant challenges for treatment. At present, negative surgical resection margin only definitive treatment despite attempts to use neoadjuvant...